氟达拉滨联合化疗治疗20例初治边缘区淋巴瘤的临床观察

目的:探讨氟达拉滨联合化疗方案治疗初治边缘区B细胞淋巴瘤的疗效和不良反应.方法:2005年9月至2010年2月期间,收治经北京肿瘤医院确诊的初治边缘区B细胞淋巴瘤患者20例,其中结外、结和脾边缘区淋巴瘤分别为16例、3例和1例.治疗方法均采用含氟达拉滨的方案,其中采用FC方案(氟达拉滨+环磷酰胺)治疗14例,采用Rituximab(利妥昔单抗,R)-FC治疗6例.所有患者均接受1～6个周期化疗,平均完成为4.3个周期.结果:20例患者中达完全缓解者18例(90%),达部分缓解者2例(10%),总有效率(完全缓解+部分缓解)为100%.所有患者的1年和2年总生存率均为88%,1年和2年无进展生存率均为88%,1年和2年的无瘤生存率均为85%.全组共化疗86个周期,主要不良反应为骨髓抑制和轻度胃肠道反应.51%周期发生白细胞下降,其中9.3%周期发生Ⅲ/Ⅳ度白细胞减少;6例(30%)患者出现血小板下降,年龄≥60岁患者中血小板下降发生率为66.7%(4/6),而<60岁患者中血小板下降发生率为14.3%(2/14),P=0.037;20%周期发生胃肠道反应;8%周期发生轻度肝功能损伤;1例(5%)患者合并肺部真菌感染.结论:氟达拉滨联合环磷酰胺对初治边缘区B细胞淋巴瘤的近期疗效较好,不良反应可耐受,远期疗效值得期待.     

氟达拉滨为主方案治疗复发难治性惰性非霍奇金淋巴瘤20例

目的 观察氟达拉滨为主方案治疗少见、复发、难治惰性非霍奇金淋巴瘤(NHL)的疗效及患者不良反应.方法 对20例少见、复发、难治性惰性NHL分别采用FMD(氟达拉滨+米托蒽醌+地塞米松)方案7例,FC(氟达拉滨联合环磷酰胺)方案8例和单用氟达拉滨5例,按照WHO疗效和不良反应评价标准进行临床评估.结果 20例患者中达完全缓解8例(40%),部分缓解9例(45%),有效率为85%.Ⅲ级以上不良反应:中性粒细胞减少共16例(80%),血小板减少共5例(25%),严重恶心、呕吐4例,轻度肝功能损害1例.结论氟达拉滨为主方案治疗少见、复发、难治性惰性NHL安全、疗效好、不良反应轻,氟达拉滨作为惰性NHL的一线治疗药物值得临床推广应用.     

氟达拉滨联合方案治疗恶性淋巴瘤的临床疗效

背景与目的：氟达拉滨是抗病毒药阿糖腺苷的氟化核苷酸类似物，用于治疗慢性淋巴细胞性白血病和复发耐药的惰性淋巴瘤已显示了疗效。本研究的目的为评价氟达拉滨联合方案治疗恶性淋巴瘤的疗效和安全性。方法：2004年1月至2005年11月间本科收治经组织学确诊的接受含氟达拉滨联合化疗的恶性淋巴瘤患者共19例，其中惰性淋巴瘤患者11例，复发的进展性淋巴瘤患者8例。11例惰性淋巴瘤患者中，6例接受了FND（氟达拉滨25mg／m^2Ⅳ d1-3；米托葸醌10mg／m^2Ⅳ d1；地塞米松20mgPOd1～5，每4周重复）方案，5例接受了FC（氟达拉滨25mg／m^2Ⅳ d1-3；环磷酰胺300mg／m^2Ⅳ d1-3，每4周重复）方案。所有进展性淋巴瘤患者均接受了FND方案。结果：接受FND或FC化疗的惰性淋巴瘤患者，有效率91％，完全缓解（CR）率45．5％。进展性淋巴瘤息者中2例达部分缓解（PR），有效率25％。全组有效率63．1％。主要不良反应为骨髓抑制。FND组有69．5％周期发生Ⅲ／Ⅳ度中性粒细胞减少。FC组无Ⅳ度中性粒细胞减少，仅22．2％周期发生Ⅲ度中性粒细胞减少。发生肺部感染4例，外阴尖锐湿疣1例。其他不良反应均为轻度，以消化道反应为主。结论：含氟达拉滨的联合方案，对于惰性淋巴瘤患者具有肯定的疗效，不良反应可以耐受。     

氟达拉滨联合异环磷酰胺治疗利妥昔单抗治疗后复发难治非霍奇金淋巴瘤21例

目的：探讨氟达拉滨联合异环磷酰胺方案对利妥昔单抗治疗后复发难治非霍奇金淋巴瘤（NHL）的治疗效果。方法21例利妥昔单抗治疗后复发难治NHL患者应用氟达拉滨联合异环磷酰胺方案联合化疗,2个月为1个周期,每个周期进行疗效及不良反应评价。结果21例患者中完全缓解4例,部分缓解9例,疾病稳定5例,疾病进展3例,临床总有效率为61.90%（13／21）。其中惰性淋巴瘤的总有效率为71.43%（5／7）,侵袭性淋巴瘤为57.14%（8／14）,两者差异无统计学意义（P＝0.656）。结论氟达拉滨联合异环磷酰胺方案治疗利妥昔单抗治疗后复发难治的NHL患者效果较好。     

氟达拉滨治疗慢性淋巴细胞白血病的近期疗效评价

 目的 研究以氟达拉滨为主的化疗方案对慢性淋巴细胞性白血病（CLL）的近期疗效。方法 24例患者中CLL／SLL 16例，CLL 4例，多毛细胞白血病1例，CLL／PLL 1例，PLL 2例。给予FC(氟达拉滨+环磷酰胺)方案，共1 ~ 4个疗程。结果 总有效率（OR）为66.67 %（16／24），完全缓解率（CR）为50 %（12／24），部分缓解（PR）为12.5 %（3／24），主要不良反应为骨髓抑制和轻度胃肠道反应，白细胞下降发生率58.33 %，血红蛋白下降发生率62.5 %，血小板下降发生率58.33 %，肝功能损害12.5 %，恶心呕吐25 %，2例死于基础疾病。结论 以氟达拉滨为主的化疗方案对CLL的近期疗效好，不良反应轻，值得近一步推广和研究。     

氟达拉滨为主的联合化疗方案治疗低度恶性非霍奇金淋巴瘤的临床观察

目的评价以氟达拉滨为主的化疗方案治疗低度恶性淋巴瘤的疗效和不良反应。方法采用氟达拉滨为主的化疗方案(FMD方案:氟达拉滨 米托蒽醌 地塞米松;FMC方案:氟达拉滨 米托蒽醌 环磷酰胺;FC方案:氟达拉滨 环磷酰胺)治疗我院收治的低度恶性非霍奇金淋巴瘤患者32例,其中初发19例,复发、难治13例。结果32例患者平均完成了4.1个疗程,完全缓解(CR)率为65.6%,部分缓解(PR)率为18.8%,总的有效(OR)率为84.4%。初发组CR率71.4%, PR率21.0%,OR率92.4%;复发、难治组CR率46.2%,PR率13.1%,OR率59.3%,两组CR率和OR率差异无统计学意义(P>0.05)。主要不良反应为骨髓抑制和免疫功能抑制。31.3%(10/32)的患者出现Ⅲ～Ⅳ级粒细胞减少,9.4%(3/32)的患者出现Ⅲ～Ⅳ级血小板减少。有7例患者出现感染、发热,其中2例肺部感染患者死亡。非血液学毒性主要为胃肠道反应及轻度的肝肾功能损害。中位随访时间16个月(1～30个月),2年总生存(OS)率(93.8±4.2)%,2年疾病无进展生存(PFS)率(84.4±6.3)%。初发组2年OS率为100%,2年PFS率为(94.7±5.0)%;复发、难治组2年OS率为(76.9±11.3)%,2年PFS率为(69.2±12.3)%,两组差异无统计学意义(P>0.05)。结论氟达拉滨为主的化疗方案患者耐受性较好,对低度恶性淋巴瘤疗效较好,有可能改善患者的预后。     

氟达拉滨联合环磷酰胺治疗惰性淋巴瘤13例

目的 观察氟达拉滨(FDR)联合环磷酰胺(CTX)方案(FC方案)治疗惰性淋巴瘤的疗效及其毒副作用.方法 收集2004年7月至2006年12月,应用FC方案治疗的13例惰性淋巴瘤患者的临床资料,在评估完全缓解(CR)率和部分缓解(PR)率的同时,观察药物毒副作用.结果 CR 6例,PR 7例,全部病均有效.中性粒细胞减少Ⅲ～Ⅳ度15.4%(2/13),Ⅱ度46.1%(6/13),白细胞(WBC)最低0.12×109/L,达最低时间为2～7 d.结论含FDR的FC方案治疗惰性淋巴瘤有较高的疗效,患者不良反应较轻,以骨髓抑制最常见,偶有胃肠道反应,未发现明显心、肝、肾脏不良反应.     

以氟达拉滨为主的联合方案治疗慢性淋巴细胞增殖性疾病10例

 目的　观察氟达拉滨（Flu）为主的联合方案治疗慢性淋巴细胞增殖性疾病（CLPD）的临床疗效和患者不良反应。方法　CLPD患者10例，男 9例，女 1例，年龄43～74岁，平均年龄60岁，其中1例接受单用Flu治疗，8例接受Flu联合环磷酰胺（FC方案）治疗，1例接受FC方案联合地塞米松治疗。结果　完全缓解（CR）4例，部分缓解（PR）6例。结论　以Flu为主的联合化疗方案治疗CLPD有效、安全。     

滤泡型淋巴瘤治疗后继发急性早幼粒细胞白血病1例报告并文献复习

目的:探讨相关性急性早幼粒细胞白血病(t-APL)的临床特点和治疗。方法:报告1例滤泡型淋巴瘤治疗后的(t-APL),并复习相关文献。结果:1例38岁的滤泡型淋巴瘤患者共接受了20疗程的化疗,包括6疗程的FND(复达拉滨、米托蒽醌、地塞米松)方案。治疗56个月后,患者出现全血细胞减少,骨髓检查诊断为APL,染色体检查为t(15;17)(q22;q12)。在应用全反式维甲酸、亚砷酸和联合化疗治疗后,获完全缓解,但16个月死于淋巴瘤复发。结论:在以复达拉滨为基础的联合化疗方案治疗滤泡型淋巴瘤时,应考虑可能发生t-APL的危险,需密切监测血细胞变化。     

氟达拉滨和环磷酰胺联合治疗慢性淋巴细胞白血病

[英 ]/Ｏ′ＢｒｉｅｎＳ…∥ＣｌｉｎＯｎｃｏｌ. 2 0 0 1,19(5 ) . 14 14～ 14 2 0 .氟达拉滨 (ｆｌｕｄａｒａｂｉｎｅ)是单药治疗慢性淋巴细胞白血病的有效药物。据报道作为慢性淋巴细胞白血病的补救性治疗 ,氟达拉滨有效率为 4 5 %～ 6 5 % ;在初治患者中达 80 % ,但完全缓解比较少见 ,常可检测到残留病灶 ,故需要一种更有效的长期治愈的方案。氟达拉滨毒性很小 ,是联合化疗的理想药物 ,其主要毒性是骨髓抑制和免疫抑制。烷化剂也是对慢淋很有效的药物 ,临床及实验研究提示环磷酰胺 (ＣＴＸ)作为烷化剂的代表 ,与氟达拉滨联合化疗治疗慢…     

Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.

PURPOSE: To evaluate the safety and efficacy of a sequential chemotherapy plus radioimmunotherapy (RIT) regimen in previously untreated follicular non-Hodgkin's lymphoma. PATIENTS AND METHODS: Thirty-five patients received an abbreviated course (three cycles) of fludarabine followed 6 to 8 weeks later by tositumomab and iodine I 131 tositumomab. RESULTS: After fludarabine, 31 (89%) of 35 patients responded, with three (9%) of 31 patients achieving a complete response (CR). After the full regimen of fludarabine and iodine I 131 tositumomab, all 35 patients responded; 30 (86%) of 35 patients achieved CR, and five (14%) of 35 achieved partial response. After a median follow-up of 58 months, the median progression-free survival (PFS) had not been reached (95% CI, 27 months to not reached), but it will be at least 48 months. The 5-year estimated PFS rate is 60%. Baseline Follicular Lymphoma International Prognostic Index (FLIPI) was significantly associated (P = .003) with PFS. Five of six patients with more than 25% bone marrow involvement at baseline achieved adequate bone marrow cytoreduction to receive standard-dose iodine I 131 tositumomab. Ten (77%) of 13 patients with baseline bone marrow Bcl-2 positivity demonstrated molecular remissions at month 12. Toxicities were manageable and principally hematologic. Two (6%) of 35 patients developed human antimurine antibodies (HAMA) after RIT. CONCLUSION: Use of abbreviated fludarabine before iodine I 131 tositumomab can reduce bone marrow involvement, when needed, to allow the use of RIT and can suppress HAMA responses. This sequential treatment regimen is highly effective as front-line therapy for follicular lymphoma, particularly for low- or intermediate-risk FLIPI patients.     

原发于上颌窦非霍奇金淋巴瘤15例临床分析

目的对原发于上颌窦非霍奇金淋巴瘤的临床、病理、治疗及预后结合文献进行分析。方法经手术后病理确诊为原发于上颌窦非霍奇金淋巴瘤15例在本院行放疗和化疗的综合治疗。放疗采用60Co-γ线或6MV~8MV高能X线,原发灶放疗中位剂量为56Gy,颈部放疗剂量为50Gy,颈部预防放疗剂量为44Gy。放射治疗前后行CHOP、COPP、COMP、BACOP等方案化疗2个~6个周期。结果5年生存率为53.4%。死亡8例,均死于远处转移。结论上颌窦非霍奇金淋巴瘤需行放射治疗和全身化疗,有条件时给予鞘内预防化疗。     

Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.

PURPOSE: To evaluate the feasibility and efficacy of rituximab with short-duration chemotherapy in the first-line treatment of patients with follicular non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS: Patients with previously untreated stage II-IV follicular NHL, grade 1 or 2, were eligible for this multicenter phase II trial. All patients received four weekly doses of rituximab (375 mg/m(2) intravenous), followed by three courses of combination chemotherapy (either cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP], or cyclophosphamide, vincristine, and prednisone [CVP]) plus rituximab. Patients were evaluated for response after completing treatment, and were then followed up at 3-month intervals. RESULTS: Between January 2000 and July 2001, 86 patients were treated. Eight-two patients (95%) completed treatment; no patient was withdrawn due to toxicity. The overall response rate was 93%, with 55% complete responses. After a median follow-up of 42 months, the 3- and 4-year actuarial progression-free survivals were 71% and 62%, respectively. Five patients (6%) died from lymphoma; the overall actuarial survival at 3 years was 95%. Grade 3/4 leukopenia occurred in 53% of patients, but only six patients (7%) had neutropenia or fever. Grade 3/4 nonhematologic toxicities were uncommon. CONCLUSION: Rituximab plus short-course chemotherapy is well tolerated as first-line treatment for patients with follicular NHL. The overall and complete response rates are similar to those reported with chemotherapy/rituximab combinations of longer duration. The actuarial progression-free survival of 62% at 4 years is encouraging, but further follow-up is necessary. Rituximab plus short-course chemotherapy may prove to be as effective as longer-duration chemotherapy and currently provides an attractive option for first-line treatment of elderly patients and others who tolerate chemotherapy poorly.     

Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study.

PURPOSE: Fludarabine (2-fluoro-arabanoside-monophosphate) is a new antimetabolite chemotherapeutic agent. We performed a multicenter, phase II study of this drug in previously treated patients with refractory or relapsed non-Hodgkin's lymphoma (NHL) to determine its response rate by histologic classification. PATIENTS AND METHODS: Sixty-two assessable patients were given 18 mg/m2 by intravenous (IV) bolus injection daily for 5 days, every 28 days. Forty-eight percent had previously had one chemotherapy regimen, and the remainder had had two regimens; 42% had had radiation. RESULTS: Patients received 273 cycles of fludarabine chemotherapy, with a median of two cycles and ranging up to 25 cycles. Sixty patients were assessable for response, including nine complete responses (CRs; 15%) and nine partial responses (PRs; 15%). The response rate for patients with lower-grade histology was 52% (13 of 25); the greatest response rate was seen in those with follicular small cleaved-cell lymphoma, including seven of 11 treated. Five responders remain in unmaintained remission; the median survival of responders is greater than 30 months. Toxicity included mild neutropenia and a 10% incidence of grade 3 neurologic toxicity with occasional reversible visual and auditory changes. CONCLUSION: Fludarabine is active in patients with previously treated NHL (particularly low-grade histologies). Future studies will examine its activity in combination with other chemotherapeutic agents in previously untreated patients.     

High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.

PURPOSE: We determined the toxicity and efficacy of a new preparative autologous bone marrow transplantation (ABMT) regimen in patients with relapsed or refractory non-Hodgkin's lymphoma or Hodgkin's disease. PATIENTS AND METHODS: Forty-four non-Hodgkin's lymphoma and 35 Hodgkin's disease patients 16 to 63 years of age were given intravenous carmustine (BCNU) 600 to 1,050 mg/m2, etoposide 2,400 to 3,000 mg/m2, and cisplatin 200 mg/m2 (BEP) and ABMT. Fifty-nine patients also received 15 to 20 Gy local radiation (involved-field radiotherapy [RI]) to active or previously bulky (> 5 cm) disease sites. RESULTS: Nonhematologic toxicities included nausea, vomiting, high-tone hearing loss, stomatitis, esophagitis, diarrhea, and hepatic and pulmonary toxicity. Two patients died within 40 days of marrow infusion as a result of sepsis and one patient died 7 months after transplant as a result of pulmonary fibrosis. Complete remissions (CRs) were noted in 72% (n = 57) of patients (n = 33 non-Hodgkin's lymphoma; n = 24 Hodgkin's disease). Forty patients (51%) remained alive and disease-free (n = 24 non-Hodgkin's lymphoma; n = 16 Hodgkin's disease) at a median of 17 (range, 8 to 57) months after marrow reinfusion. CONCLUSIONS: This regimen seems to be effective for relapsed lymphoma patients whose disease continues to exhibit chemotherapy sensitivity (16 of 24 [67%] disease-free). Furthermore, this regimen seems to be effective in patients who have never attained a CR (seven of 19 [37%] disease-free).     

The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma.

PURPOSE: The study was undertaken to assess whether immunotherapy regimens with bolus high-dose interleukin-2 (IL-2) alone or with lymphokine-activated killer (LAK) cells are active in previously treated, relapsed patients with non-Hodgkin's lymphoma. PATIENTS AND METHODS: Nineteen patients with low- or intermediate-grade lymphomas were treated with bolus high-dose IL-2 alone (11 patients) or IL-2 with LAK cells (eight patients). IL-2 was administered by intravenous bolus infusion at 720,000 IU/kg every 8 hours. Eight patients had low-grade histologies; 11 patients were intermediate-grade. Eighteen patients had received second- or third-generation combination chemotherapy, and eight had also received radiation. All 19 relapsed after a median of two chemotherapy regimens. RESULTS: Four responses were observed, three partial and one complete, in patients with follicular histologies who received IL-2 with LAK cells. Response durations were 10, 16, 16, and 26 months, and three responders were re-treated after relapse with subsequent disease control for an additional 16, 39+, and 2+ months, respectively. CONCLUSION: High-dose, bolus IL-2-based immunotherapy with LAK cells may be an effective treatment for patients with non-Hodgkin's lymphoma and merits further testing with larger numbers of patients in phase II trials.     

Limited stage I and II follicular non-Hodgkin's lymphoma: the Nebraska Lymphoma Study Group experience

The purpose of this study was to evaluate the outcome and prognostic factors of patients with limited stage follicular non-Hodgkin's lymphoma treated prospectively by the Nebraska Lymphoma Study Group (NLSG). Forty previously untreated patients, median age 64 years, with limited stage follicular lymphoma were prospectively treated according to the protocols of the NLSG between January 1980 and December 1990. The follicular large cell type represents 75% of the cases, and 14 of the biopsies also had a diffuse component (composite lymphoma). The initial treatment was radiation therapy (RT) to the involved field in 15 patients, anthracycline-containing combination chemotherapy (CT) in 20, and combined RT and CT in 5. Thirty-seven patients (92.5%) achieved a complete remission (CR). The median follow-up is 120 months (range, 20 to 214). Of the 37 patients achieving a CR, 7 patients are alive in first CR, one died due to sepsis, another because of a myeloproliferative disorder at 77 months following chemotherapy, 6 died because of unrelated causes in first CR. Twenty-two patients relapsed between 1 to 128 months following a CR. The estimated 10-year event-free survival is 21% (95% CI: 7 to 35). Two patients received no or palliative therapy after relapse and both died of progressive disease. Nineteen patients received salvage therapy and 15 achieved a second remission. The median survival after first relapse is 55 months. The estimated 10-year overall survival is 44% (95% CI: 28 to 60). Various factors including sex, histologic subtype, stage, and degree of follicularity do not influence the overall survival or event-free survival. CT with or without RT resulted in a better trend for 10-year event-free survival in stage IA patients compared to RT alone but estimated 10-year overall survival is no different. The overall survival is worse in the > or = 60 age group but this difference is not evident if data is adjusted for cause specific death. In conclusion, limited stage follicular lymphoma has an excellent initial response to radiation therapy or chemotherapy; however the recurrence rate is high and cure is limited.     

EPOCH方案治疗复发耐药NHL临床疗效

目的：评价EPOCH方案作为挽救方案的疗效及耐受性。方法：2004年6月至2006年12月应用EP-OCH方案治疗我院收治的复发耐药中高度恶性非霍奇金淋巴瘤（NHL）31例，每例至少接受过2个化疗方案的治疗，采用VP-1650mg／m^2/d、ADM或THP10mg／m^2／d、VCR0．4mg／m^2／d持续静脉滴注第1—4天。CTX750mg／m^2／d静推第6天，强的松60rag／m^2／d口服第1—5天，21天为1个疗程。结果：评价疗效者31例，评价不良反应疗程数为67，总有效率54．9％，其中完全缓解6例（19．4％），部分缓解11例（35．5％）。不良反应为骨髓抑制，其他系统不良反应少见。结论：EPOCH作为复发耐药中高度恶性NHL的挽救化疗方案经济有效，毒性可耐受。通过持续静脉滴注的给药途径可能减低肿瘤细胞的耐药率和化学毒性。     

Combination Chemotherapy Specifically Devised for Elderly Patients with Unfavorable Non-Hodgkin's Lymphoma

The results of a prospective trial with a specifically devised chemotherapy regimen in elderly patients with unfavorable non-Hodgkin's lymphoma (NHL) are reported. Between April 1983 and April 1986, 37 consecutive patients 70 years old or more (median age 80) received etoposide and prednimustine (E%P) 100 mg/m² p.o. for 5 days every 21 days. Thirteen patients were previously treated. Objective response rate in the 35 evaluable patients is 66% with 46% complete response. The objective response rate in the 22 previously untreated patients is nearly 70% with 50% complete response. Median survival is 14 months. The overall toxicity was reasonably acceptable. There were 5% (2 patients) treatment-related deaths, but in an unselected elderly population. We experienced the usefulness of a properly oriented clinical approach to elderly patients with NHL. We suggest that a combination regimen E%P, suitable for oral administration, may be safely employed in elderly patients with unfavorable NHL.     

Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, prednisolone (VEPA) in non-Hodgkin's lymphoma, with special reference to correlation of surface phenotype with response and survival

Thirty-seven previously untreated patients with advanced non-Hodgkin's lymphoma were treated with VEPA therapy. The complete remission (CR) rate was higher in the patients with diffuse B-cell lymphoma (75%) than in those with follicular B-cell lymphoma (20%) and T-cell lymphoma (42%). Two characteristics, i.e., elevated LDH and bone marrow involvement, were negatively associated with response rate in patients with diffuse lymphoma (B-, T-). The median duration of CR has not yet been reached, and the 2-year relapse-free rate was 64% for cases of diffuse B-cell lymphoma, while for T-cell lymphoma patients, the median duration of CR was 7 months. For diffuse B-cell lymphoma patients, the median survival has not yet been reached, and the 2-year survival rate was 57%. On the other hand, median survival for T-cell lymphoma patients was 12 months. VEPA therapy was less effective for the treatment of T-cell lymphoma, and a more intensive regimen should therefore be designed to overcome the potential aggressiveness of T-cell lymphoma.